170 related articles for article (PubMed ID: 32201337)
21. Transcript and protein marker patterns for the identification of steatotic compounds in human HepaRG cells.
Lichtenstein D; Mentz A; Schmidt FF; Luckert C; Buhrke T; Marx-Stoelting P; Kalinowski J; Albaum SP; Joos TO; Poetz O; Braeuning A
Food Chem Toxicol; 2020 Nov; 145():111690. PubMed ID: 32810590
[TBL] [Abstract][Full Text] [Related]
22. Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.
Pelkonen O; Terron A; Hernandez AF; Menendez P; Bennekou SH;
Arch Toxicol; 2017 Aug; 91(8):2763-2780. PubMed ID: 28536863
[TBL] [Abstract][Full Text] [Related]
23. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells.
Tanner N; Kubik L; Luckert C; Thomas M; Hofmann U; Zanger UM; Böhmert L; Lampen A; Braeuning A
Drug Metab Dispos; 2018 Apr; 46(4):326-335. PubMed ID: 29330220
[TBL] [Abstract][Full Text] [Related]
24. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways.
Mellor CL; Steinmetz FP; Cronin MT
Crit Rev Toxicol; 2016 Feb; 46(2):138-52. PubMed ID: 26451809
[TBL] [Abstract][Full Text] [Related]
25. Assessment of mixture toxicity of (tri)azoles and their hepatotoxic effects in vitro by means of omics technologies.
Seeger B; Mentz A; Knebel C; Schmidt F; Bednarz H; Niehaus K; Albaum S; Kalinowski J; Noll T; Steinberg P; Marx-Stoelting P; Heise T
Arch Toxicol; 2019 Aug; 93(8):2321-2333. PubMed ID: 31254001
[TBL] [Abstract][Full Text] [Related]
26. [Molecular Pathway and AOP Development Using Gene Network Analysis].
Tanabe S; Hirose A; Whelan M; Yamada T
Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
[TBL] [Abstract][Full Text] [Related]
27. Exposure to an environmentally relevant mixture of organochlorine compounds and polychlorinated biphenyls Promotes hepatic steatosis in male Ob/Ob mice.
Mulligan C; Kondakala S; Yang EJ; Stokes JV; Stewart JA; Kaplan BL; Howell GE
Environ Toxicol; 2017 Apr; 32(4):1399-1411. PubMed ID: 27533883
[TBL] [Abstract][Full Text] [Related]
28. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
Yamada T; Ashikaga T; Kojima H; Hirose A
Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
[TBL] [Abstract][Full Text] [Related]
29. Adverse outcome pathway development from protein alkylation to liver fibrosis.
Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
[TBL] [Abstract][Full Text] [Related]
30. Quantification of an Adverse Outcome Pathway Network by Bayesian Regression and Bayesian Network Modeling.
Moe SJ; Wolf R; Xie L; Landis WG; Kotamäki N; Tollefsen KE
Integr Environ Assess Manag; 2021 Jan; 17(1):147-164. PubMed ID: 32965776
[TBL] [Abstract][Full Text] [Related]
31. Is there a role for the adverse outcome pathway framework to support radiation protection?
Chauhan V; Said Z; Daka J; Sadi B; Bijlani D; Marchetti F; Beaton D; Gaw A; Li C; Burtt J; Leblanc J; Desrosiers M; Stuart M; Brossard M; Vuong NQ; Wilkins R; Qutob S; McNamee J; Wang Y; Yauk C
Int J Radiat Biol; 2019 Feb; 95(2):225-232. PubMed ID: 30373433
[TBL] [Abstract][Full Text] [Related]
32. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach.
van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M
J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407
[TBL] [Abstract][Full Text] [Related]
33. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
34. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
Kim M; Kim SH; Choi JY; Park YJ
Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
[TBL] [Abstract][Full Text] [Related]
35. An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.
Terron A; Bal-Price A; Paini A; Monnet-Tschudi F; Bennekou SH; ; Leist M; Schildknecht S
Arch Toxicol; 2018 Jan; 92(1):41-82. PubMed ID: 29209747
[TBL] [Abstract][Full Text] [Related]
36. AOP4EUpest: mapping of pesticides in adverse outcome pathways using a text mining tool.
Jornod F; Rugard M; Tamisier L; Coumoul X; Andersen HR; Barouki R; Audouze K
Bioinformatics; 2020 Aug; 36(15):4379-4381. PubMed ID: 32467965
[TBL] [Abstract][Full Text] [Related]
37. Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.
Arnesdotter E; Gijbels E; Dos Santos Rodrigues B; Vilas-Boas V; Vinken M
Methods Mol Biol; 2022; 2425():521-535. PubMed ID: 35188645
[TBL] [Abstract][Full Text] [Related]
38. Acceleration of murine hepatocyte proliferation by imazalil through the activation of nuclear receptor PXR.
Yoshimaru S; Shizu R; Tsuruta S; Amaike Y; Kano M; Hosaka T; Sasaki T; Yoshinari K
J Toxicol Sci; 2018; 43(7):443-450. PubMed ID: 29973476
[TBL] [Abstract][Full Text] [Related]
39. Identification of molecular initiating events (MIE) using chemical database analysis and nuclear receptor activity assays for screening potential inhalation toxicants.
Jeong J; Kim J; Choi J
Regul Toxicol Pharmacol; 2023 Jun; 141():105391. PubMed ID: 37068727
[TBL] [Abstract][Full Text] [Related]
40. Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
Pant A; Rondini EA; Kocarek TA
Toxicol Appl Pharmacol; 2019 Feb; 365():61-70. PubMed ID: 30611723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
